Results

Total Results: 1,187 records

Showing results for "weeks".

1041. OUTLINE (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-end-of-life-measures-framework_research.pdf
      April 01, 2010 - Indicators about aggressiveness of care at the end of life (such as chemotherapy in the last two weeks … Care of the imminently dying Prognosis Percentage of patients with chemotherapy in the last two weeks

1042. PHARMACO-EPIDEMIOLOGIC METHODS FOR A STUDY OF (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotic-medicine-mortality-elderly_research.pdf
      March 01, 2009 - period was chosen based upon the duration of trials in the FDA’s reanalysis (which ranged from 4-26 weeks … , with a modal duration of 10 weeks). 8 Unadjusted and multivariable (adjusting for calendar year

1043. OUTLINE (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-quality-indicator-framework_research.pdf
      April 01, 2010 - Indicators about aggressiveness of care at the end of life (such as chemotherapy in the last two weeks … Care of the imminently dying Prognosis Percentage of patients with chemotherapy in the last two weeks

1044. Version 2_Risk of Reinfection From SARS-CoV-2 -- An Update of an Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-2-risk-of-reinfection-from-SARSCoV2_0.pdf
      December 31, 2022 - research studies, we searched (1) Ovid MEDLINE ALL, WHO COVID, and ClinicalTrials.gov roughly every 2 weeks … were not always adequate to accurately detect symptoms that were present at the time of, or in the weeks … cohort United States Recovery: Participants aged 21 years and younger and enrolled within 12 weeks … Convalescent: Participants aged 21 years and younger and enrolled more than 12 weeks after acute infection

1045. Antibiotics-Respiratory-Infection Clinician (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/antibiotics-respiratory-infection_clinician.pdf
      March 01, 2016 - 0.73 (95% CI, 0.60 to 0.90) 7 RCTs ��� Adverse consequences — Greater reconsultation rate within 4 weeks

1046. Disposition of Comments Report for Comparison of Characteristics of Nursing Homes and Other Residential Long-Term Care Settings for People With Dementia (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/dementia-nursing-home-characteristics_disposition-comments.pdf
      October 23, 2012 - the functional skill training studied was conducted 5 days per week for 2.5 hours per day over 20 weeks … the functional skill training studied was conducted 5 days per week for 2.5 hours per day over 20 weeks

1047. new disposition of comments insulin analogues -- jda revs.xls (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/insulin-analogues-disposition-081229.pdf
      September 01, 2008 - glulisine in diabetes mellitus, type 2) ClinicalTrials.gov Identifier: NCT00174668 Treatment period: 52 weeks … With Oral Agents (All to Target Trial) ClinicalTrials.gov Identifier: NCT00384085 Treatment period: 64 weeks

1048. Kravitz_ECCS2012 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/kravitz_eccs2012.pdf
      January 01, 2012 - Kravitz_ECCS2012 Slide 1: Media, Messages, and Medication: Strategies  To Reconcile What Patients  Hear, What TheyWant, andWhat They Need FromMedications   Richard  L.  Kravitz,  M.D.,  M.S.P.H. University of California, Davis, Department of…

1049. #05 DEPRESSION (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1312.pdf
      October 01, 2014 - preliminary data have indicated it produces a rapid (within 2 hours) and relatively sustained (about 1–2 weeks … small opening behind the ear and connects the electrode to the neurostimulator.25 Between 2 and 4 weeks … symptoms improved both significantly and rapidly and that these effects lasted from 3 days to several weeks

1050. Future Research Needs for Noncyclic Chronic Pelvic Pain Therapies for Women (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/pelvic-pain-therapies-future_research.pdf
      January 01, 2015 - pain is the placebo effect, which in analgesic trials is often substantial and may have a duration of weeks … To enhance public engagement, the draft report will be made available for public input for four weeks … inaction • Potential to address inequities We sent a link to the second survey approximately 2 weeks … dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks

1051. Future Research Needs for Treatment of Obstructive Sleep Apnea (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/sleep-apnea-treatment-future_research.pdf
      February 01, 2012 - The original plan was for the stakeholder discussion to last 2 weeks; in reality, the discussion period … Since outcomes generally change rapidly (within a few weeks or months) after the start of treatment, … Since symptoms generally change rapidly (within a few weeks) after the start of treatment, data could

1052. Disposition of Comments Report for Chronic Venous Ulcers: A Comparative Effectiveness Review of Treatment Modalities (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/venous-ulcers-treatment_disposition-comments.pdf
      January 27, 2014 - The Jull study included patients who had venous ulcers for only 2 weeks. … patients with chronic venous ulcers, meaning patients must have had an active ulcer for at least 6 weeks … of chronic venous leg ulcers only and did not evaluate evidence on ulcers present for less than 6 weeks … Nowhere in wound care is one going to use the same therapy for 12, 16 or 20 weeks.

1053. Pressure-Ulcer-Treatment Executive (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/pressure-ulcer-treatment_executive.pdf
      May 01, 2013 - advanced ulcers may not be expected to achieve complete wound healing over the course of several weeks … To obtain public comment, the draft report was posted on the AHRQ Web site for 4 weeks. … Interventions lasting only a few weeks (as was the case for most of the trials included in our review … of studies in our review was the duration of interventions and followup periods, typically a few weeks

1054. Comparative Effectiveness of β-Adrenergic Antagonists on the Risk of Rehospitalization in Adults with Heart Failure (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/heart-failure-rehospitalization_research.pdf
      November 01, 2007 - PRIOR_MI OSCR 4109.002 Myocardial infarc PRIOR_MI OSCR 41090.001 History of myocardial infarction <8 weeks … Cardiac MI PRIOR_MI OSCR 41091.001 Myocardial infarction PRIOR_MI OSCR 4109.001 History of MI < 8 weeks … PRIOR_MI OSCR 41092.001 Recent MI < 8 weeks PRIOR_MI OSCR 411.001 MI (S/P) PRIOR_MI ICD9D 412 Old … of Myocardial infarction (MI) PRIOR_MI OSCR 412.003 Old MI PRIOR_MI OSCR 412.004 History of MI > 8 weeks … PRIOR_MI OSCR 412.005 Myocardial infarct (MI), OLD (>8 Weeks) PRIOR_MI OSCR 412.900 History of MI

1055. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/cystic-fibrosis-hgh_research-protocol.pdf
      August 22, 2008 - Evidence-based Practice Center Systematic Review Protocol Source: www.effectivehealthcare.ahrq.gov Published Online: January 22, 2010 1 Evidence-based Practice Center Systematic Review Protocol Project Title: Effectiveness of Recombinant Human Growth Hormone in the Treatment of Cystic Fibrosis…

1056. CARDIOVASCULAR (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/cardiovascular-horizon-scan-high-impact-1412.pdf
      December 01, 2014 - lomitapide at a median dose of 40 mg per day reduced LDL-C concentrations by a mean of 50% at 26 weeks … escalate dosage gradually based on acceptable safety and tolerability to 10 mg daily after at least 2 weeks … Lomitapide reduced LDL-C concentrations by a mean of 50% at 26 weeks from baseline.

1057. Rotator-Cuff-Tear-Surveillance-140925 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/rotator-cuff-tear-surveillance-140925.pdf
      February 01, 2014 - hyaluronate had improved function (Constant score) and pain (VAS) compared to patients on placebo 6 weeks … Limited passive rehabilitation (n=42; continuous passive motion exercise, self-passive exercise) 6 weeks … PL (6 weeks post-treat ment) Constant score: 79.24 ± 13.09 vs. 69.07 ± 13.29, p=0.0095 Pain (VAS):

1058. Ch 4-User-Guide-To-Ocer 130129 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/ch_4-user-guide-to-ocer_130129.pdf
      January 01, 2010 - cardiovascular events, which would be over the preceding several years rather than, for instance, over the 2 weeks

1059. Antipsychotics-Adults Surveillance (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/antipsychotics-adults_surveillance.pdf
      August 30, 2014 - Mortality SOE: Low – No differences found • Chlorpromazine vs. clozapine (2 studies) - at 52 and 208 weeks … change on mania rating scales and the number of patients who dropped out of the allocated treatment at 3 weeks … studies) - at 52 and 208 weeks other reviewer recommended examining • Haloperidol vs. aripiprazole (

1060. FRN 27 - Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation: Future Research Needs (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/wireless-motility-capsule-future_research.pdf
      May 01, 2013 - In normal patients and those with gastroparesis, how reproducible are WMC studies performed 2 weeks … In normal patients and those with gastroparesis, how reproducible are WMC studies performed 2 weeks apart … In normal patients and those with gastroparesis, how reproducible are WMC studies performed 2 weeks … In normal patients and those with gastroparesis, how reproducible are WMC studies performed 2 weeks apart